Regeneron Pharmaceuticals (REGN.US) Q3 results exceed expectations, raises full-year net product margin guidance

According to Zhitong Finance APP, Regeneron Pharmaceuticals (REGN.US) has released its results for the third quarter of 2026: total revenue was $5.1158 billion, an increase of 36.3% year-on-year, exceeding the IBES consensus expectation of $4.542 billion. GAAP diluted earnings per share were $18.45, up 35.5% year-on-year. Non-GAAP diluted earnings per share were $20.07, up 69.7% year-on-year, about 24% higher than the IBES forecast of $16.20.